Results for "consumer data right"
451-460 of 558 results for 'consumer data right'
Summary of proposed reforms to FIRB regime – Tranche 2 Regulations
On 18 September 2020 the Federal Government released exposure drafts of the 'Tranche 2 Regulations' to amend Australia's foreign investment laws. This follows the release on 31 July 2020 of the 'Tranc ...
ASIC's New Document Production Guidelines
ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...
Proposed RG 97 stamp duty and PHD private credit changes on the horizon
ASIC has announced proposed: limited changes to the way stamp duty will be disclosed under Regulatory Guide 97 Disclosing fees and costs in PDSs and periodic statements (RG 97), which are the rules f ...
The pitfalls of pre-emptive rights
In this Insight, we consider an alternative approach that may better balance the rights of selling and non-selling investors where a pre-emptive right remains appropriate. ...
Roadblocks remain for design protection of Graphical User Interfaces in Australia
Two recent decisions by IP Australia have confirmed that Graphical User Interfaces (GUIs) are not certifiable as designs under the Designs Act, due to their transient nature and IP Australia's narrow ...
FIRB changes to note from 1 July 2023
In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...
Dollars and sense: the evolution of executive remuneration practices
The need for robust executive remuneration frameworks is becoming increasingly important as companies tackle the challenges arising out of the COVID-19 pandemic, a heightened regulatory environment and the need to strike the right balance with executives to drive and reward conduct and performance t ...
COVID-19 and continuous disclosure: how you get ready
It is critical that listed entities understand how COVID-19 is likely to impact their businesses and are prepared to make necessary disclosures to the ASX. To date, the majority of ASX-listed entities have not made any disclosure in relation to COVID-19. In this update we have set out a number of scenarios that should be considered by listed clients as part of the proper and ongoing assessment of the need for disclosure under the ASX Listing Rules. ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...